Onzima Ventures Share Discussion Threads

[keya5000] 31/3/2017 14:51

cpap, GB is leaving on relist.

[keya5000] 31/3/2017 14:51

cpap, GB is leaving on relist.

[keya5000] 31/3/2017 14:51

cpap, GB is leaving on relist.

[cpap man] 31/3/2017 11:35

It should be noted that Burnell & Cairns are here but otherwise it does look quite interesting!

[herschel k] 31/3/2017 11:11

Corporate action with open offer confirmed by AJ Bell yesterday evening for my ISA and SIPP.

Might take some.

H

[herschel k] 30/3/2017 14:04

thanks Keya, appreciated.

makes sense now!

[meganxmas] 30/3/2017 13:29

all above noted .. certainly nothing out there yet other than in annual report. wait with interest ....

[keya5000] 30/3/2017 12:28

Not been made inside so happy to share the above.

One thing for sure NT is looking after us or at least trying his very best to do so.

[keya5000] 30/3/2017 12:19

All,

They are doing a 4/1 reorganisation.

Looking for £4m. £3m raise -- £1m open offer.

Had tried to get it away at 3.7p/15.6p but take up was weak from those who are backing with the thought process that existing holders would sell from the start and trash the share price

So that unfortunately got reduced to 9p then 7p so 1.75 in effect.

This is going places on re-list all parties value the business much higher but the funders would not cover such a gap.

Could be confirmed today.

[herschel k] 30/3/2017 12:06

WL,

Sorry, but that doesn't make sense.............unless they are proposing a share consolidation at the same time.

H

[flashheart] 30/3/2017 11:53

Yes I've not seen that either.

[westmoreland lad] 30/3/2017 11:53

Megan -- not sure of the original author but he / she stated -------

''You are not inside as Onzima (ONZ.L) is currently suspended and the information has been disclosed to the market ''

OK

[meganxmas] 30/3/2017 11:34

where did you get the info re placing price etc ?thanks

[westmoreland lad] 30/3/2017 11:29

Anyone go for placing shares ?

Raising a minimum of £1.65m at 7p per share .One for one warrant at 8.5p, 18 month life. As part of the transaction ONZ will acquire the remaining 51% of N4 Pharma .

PS -- Nobody inside, ie. all in the public domain.

[flashheart] 29/3/2017 14:30

Should do well on its re-listing I would think. N4 is indeed a bright prospect.

[barrie16] 29/3/2017 14:10

I read in the press,sildenafil is to be sold over the counter at pharmacies, without a prescription. I can imagine the drug in tablet form selling very well. The future seems bright for N4.

[westmoreland lad] 29/3/2017 11:41

Someuwin -- re your post 535

Looks like game on, along with the remaining 51% of N4 Pharma it does not already own.

Should relist on AIM mid April.

[barrie16] 06/3/2017 19:33

gnnmartin
It does sound very similar to N4s. Certainly further advanced. Is that good or bad?

[gnnmartin] 06/3/2017 18:33

I was intrigued today to read an email from Proactivity saying that Futura Medical is developing a fast acting OTC treatment for erectile disfunction. Sounds like N4's, but with a bit more details. Competition, I assume.

[luminoso] 17/1/2017 18:24

Makes it much more focussed and I'll be interested in getting back in, depending on price at re-entry.

[bdog51] 17/1/2017 12:17

The RNS we were all waiting / hoping for. Welcome news in the face of much skepticism of late ;-) And a return to trading from mid-April, not too long to wait in the grand scheme of things.

[curlly] 17/1/2017 11:30

that is good at least we are back in play

[jakleeds] 17/1/2017 11:04

Hmmm.. light at the end of the tunnel ?

[gnnmartin] 17/1/2017 10:50

Pleased to see there is life after death.

[someuwin] 17/1/2017 10:43

17 January 2017

Onzima Ventures plc

("Onzima" or the "Company")

Proposed Acquisition, Strategic Update

and

Appointment of Nominated Adviser and Broker

Onzima is pleased to announce that it has agreed in principle terms conditionally to acquire the 51 per cent. of the issued shares of N4 Pharma Limited ("N4 Pharma") which it does not already own (the "Proposed Acquisition"). The consideration for the Proposed Acquisition will be satisfied by the issue of 36,409,210 new ordinary shares of 0.1p each in the capital of Onzima ("Ordinary Shares"). It is intended that at the same time the Company will seek to raise approximately GBP3.0 million by way of a placing of new Ordinary Shares to fund development of additional patented reformulations of a wider range of generic drugs, to undertake clinical trials for the Company's reformulation of Sildenafil and for working capital purposes.

The Proposed Acquisition will be classified as a reverse takeover under the AIM Rules for Companies and, as a result, is subject to the publication of an admission document in respect of the Company as enlarged by N4 Pharma setting out full details of the Proposed Acquisition and convening a general meeting of the Company where shareholders' approval will be sought for, among other things, the Proposed Acquisition and to change the Company's name to N4 Pharma plc (the "Admission Document").

Onzima is gradually monetising its share portfolio to provide funds for the continued development of N4 Pharma and the costs of the Proposed Acquisition. Following completion of the Proposed Acquisition, its trading division will cease to exist. Onzima has today agreed to increase its loan facility to N4 Pharma from GBP209,000 to GBP309,000.

In anticipation of the Proposed Acquisition, the Company has appointed Stockdale Securities Limited as its nominated adviser and broker with immediate effect.

It is expected that, subject to the completion of satisfactory due diligence, preparation of the requisite documentation and obtaining shareholders' approval, the Proposed Acquisition will be completed in mid-April 2017 ("Completion"). On Completion, it is expected that new directors will be appointed to the board of Onzima, including Nigel Theobald, the founder and Chief Executive of N4 Pharma, and that Professor Mughal and Gavin Burnell will step down as directors of the Company.

It is expected that the temporary suspension of trading on AIM in the Ordinary Shares will remain until Completion.

Further announcements will be made in due course.